CRMD has 36-month beta value of 1.62. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRMD is 56.86M, and currently, short sellers hold a 16.30% ratio of that float. The average trading volume of CRMD on October 17, 2024 was 836.54K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRMD) stock’s latest price update
CorMedix Inc (NASDAQ: CRMD)’s stock price has soared by 0.38 in relation to previous closing price of 10.45. Nevertheless, the company has seen a gain of 7.81% in its stock price over the last five trading days. globenewswire.com reported 2024-09-13 that BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024.
CRMD’s Market Performance
CorMedix Inc (CRMD) has experienced a 7.81% rise in stock performance for the past week, with a 44.79% rise in the past month, and a 125.59% rise in the past quarter. The volatility ratio for the week is 5.21%, and the volatility levels for the past 30 days are at 5.82% for CRMD. The simple moving average for the last 20 days is 18.14% for CRMD’s stock, with a simple moving average of 110.35% for the last 200 days.
Analysts’ Opinion of CRMD
Many brokerage firms have already submitted their reports for CRMD stocks, with Rodman & Renshaw repeating the rating for CRMD by listing it as a “Buy.” The predicted price for CRMD in the upcoming period, according to Rodman & Renshaw is $13 based on the research report published on August 26, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see CRMD reach a price target of $6. The rating they have provided for CRMD stocks is “Outperform” according to the report published on August 10th, 2023.
Needham gave a rating of “Buy” to CRMD, setting the target price at $31 in the report published on February 17th of the previous year.
CRMD Trading at 50.64% from the 50-Day Moving Average
After a stumble in the market that brought CRMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.59% of loss for the given period.
Volatility was left at 5.82%, however, over the last 30 days, the volatility rate increased by 5.21%, as shares surge +49.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +165.48% upper at present.
During the last 5 trading sessions, CRMD rose by +7.50%, which changed the moving average for the period of 200-days by +177.45% in comparison to the 20-day moving average, which settled at $8.88. In addition, CorMedix Inc saw 178.99% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRMD starting from Todisco Joseph, who purchase 13,561 shares at the price of $3.74 back on Mar 13 ’24. After this action, Todisco Joseph now owns 352,839 shares of CorMedix Inc, valued at $50,718 using the latest closing price.
DUNTON ALAN W, the Director of CorMedix Inc, purchase 3,000 shares at $3.45 during a trade that took place back on Dec 14 ’23, which means that DUNTON ALAN W is holding 12,250 shares at $10,350 based on the most recent closing price.
Stock Fundamentals for CRMD
Current profitability levels for the company are sitting at:
- -52.37 for the present operating margin
- -0.29 for the gross margin
The net margin for CorMedix Inc stands at -47.84. The total capital return value is set at -1.25. Equity return is now at value -111.55, with -92.57 for asset returns.
Based on CorMedix Inc (CRMD), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -85.46. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1612.34.
Currently, EBITDA for the company is -48.89 million with net debt to EBITDA at 0.49. When we switch over and look at the enterprise to sales, we see a ratio of 522.4. The receivables turnover for the company is 1.57for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.79.
Conclusion
To put it simply, CorMedix Inc (CRMD) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
